XML 42 R33.htm IDEA: XBRL DOCUMENT
v3.22.1

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 5,011 | $ 4,907 | $ 10,006 | $ 10,223
Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,416 | 2,311 | 4,813 | 4,572
Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,485 | 1,586 | 2,968 | 3,565
Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,111 | 1,011 | 2,225 | 2,086
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,807 | 2,462 | 5,659 | 5,592
United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,314 | 1,220 | 2,671 | 2,494
United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 747 | 576 | 1,490 | 1,710
United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 746 | 666 | 1,498 | 1,388
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,204 | 2,446 | 4,347 | 4,631
International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,102 | 1,091 | 2,142 | 2,078
International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 738 | 1,010 | 1,478 | 1,855
International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 364 | 345 | 727 | 698
Medication Delivery Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,038 | 999 | 2,122 | 2,006
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 588 | 531 | 1,207 | 1,099
Medication Delivery Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 450 | 468 | 915 | 908
Medication Management Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 604 | 566 | 1,231 | 1,196
Medication Management Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 461 | 440 | 945 | 917
Medication Management Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 143 | 126 | 286 | 278
Diabetes Care | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 273 | 284 | 561 | 569
Diabetes Care | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 140 | 148 | 291 | 298
Diabetes Care | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 133 | 135 | 271 | 271
Pharmaceutical Systems | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 501 | 462 | 898 | 801
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 125 | 100 | 228 | 180
Pharmaceutical Systems | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 376 | 361 | 670 | 621
Integrated Diagnostic Solutions | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,150 | 1,261 | 2,295 | 2,928
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 618 | 454 | 1,232 | 1,469
Integrated Diagnostic Solutions | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 532 | 807 | 1,062 | 1,459
Biosciences | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 335 | 325 | 674 | 637
Biosciences | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 129 | 121 | 258 | 241
Biosciences | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 206 | 204 | 416 | 396
Surgery | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 340 | 292 | 701 | 624
Surgery | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 268 | 227 | 549 | 489
Surgery | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 72 | 65 | 152 | 135
Peripheral Intervention | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 450 | 420 | 863 | 846
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 240 | 222 | 457 | 454
Peripheral Intervention | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 210 | 198 | 407 | 392
Urology and Critical Care | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 320 | 298 | 661 | 616
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 239 | 217 | 492 | 445
Urology and Critical Care | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 82 | $ 82 | $ 168 | $ 171

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_IntegratedDiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |